Skip to main content
. 2018 Mar 29;41(6):1251–1259. doi: 10.2337/dc18-0040

Table 3.

Associations of MS at baseline with baseline and longitudinal ALT values and APRI scores using multivariable analysis*

Variables Baseline and longitudinal ALT levels (n = 734)
Baseline and longitudinal APRI scores (n = 687)
Ratio 95% CI P value Ratio 95% CI P value
MS (vs. no MS) 1.12 1.02–1.22 0.02 0.91 0.82–1.01 0.06
Age, per decade (years) 1.00 0.97–1.03 0.87 1.08 1.04–1.12 <0.0001
Female sex (vs. male sex) 0.73 0.68–0.78 <0.0001 0.81 0.76–0.88 <0.0001
Race (vs. white)
 Asian 0.89 0.79–1.00 0.052 0.81 0.77–0.99 0.03
 Black 0.87 0.75–1.00 0.056 0.84 0.71–0.98 0.03
 Other 0.94 0.76–1.17 0.59 0.99 0.78–1.26 0.95
Alcohol use in past 12 months (vs. none)
 Moderate 1.00 0.92–1.10 0.92 1.01 0.92–1.11 0.84
 At risk 1.05 0.91–1.21 0.52 1.03 0.88–1.21 0.67
Birth/immigration status (vs. foreign-born and immigrated ≤20 years ago)
 Born in U.S./Canada or foreign-born and immigrated >20 years ago 0.95 0.88–1.03 0.20 0.99 0.91–1.07 0.71
 Foreign-born but unknown date of immigration 0.98 0.81–1.18 0.83 0.94 0.77–1.14 0.53
Family history of diabetes (vs. none) 1.03 0.96–1.11 0.36 0.98 0.91–1.06 0.65
Log10 HBV DNA (IU/mL) 1.21 1.20–1.22 <0.0001 1.16 1.15–1.18 <0.0001
HBeAg positive (vs. negative) 0.85 0.78–0.93 0.0006 0.91 0.82–1.00 0.0500

*Analysis was also controlled for duration of follow-up, receipt of HBV therapy, and duration of HBV therapy.

†Factor by which the mean ALT value or APRI score differs for the comparator vs. the reference.

‡Measured at baseline and longitudinally.